USANA Health Sciences (NYSE:USNA) Announces Earnings Results

USANA Health Sciences (NYSE:USNA) posted its quarterly earnings data on Tuesday. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07, Yahoo Finance reports. The company had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same quarter in the previous year, the firm earned $0.59 earnings per share. USANA Health Sciences updated its FY 2024 guidance to 2.450-2.450 EPS.

USANA Health Sciences Trading Up 3.2 %

Shares of USNA traded up $1.10 during trading hours on Wednesday, hitting $35.58. 11,590 shares of the stock traded hands, compared to its average volume of 79,591. USANA Health Sciences has a 1-year low of $34.15 and a 1-year high of $55.45. The firm has a market capitalization of $677.83 million, a PE ratio of 10.55, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. The business has a fifty day moving average of $38.02 and a 200-day moving average of $42.59.

Analyst Ratings Changes

A number of research firms have commented on USNA. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday. StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th.

Insider Activity

In other news, Director John Turman Fleming sold 1,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now owns 2,503 shares of the company’s stock, valued at $111,208.29. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Turman Fleming sold 1,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the sale, the director now owns 2,503 shares of the company’s stock, valued at $111,208.29. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock valued at $311,670 over the last 90 days. 0.33% of the stock is owned by company insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.